Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced that, under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions Inc, it has identified new pharmacological insights related to the mechanisms of action and bioavailability of 5-MeO-DMT and other first-generation psychedelics.
Specifically, Mindset said it has further developed standard pharmacokinetics and drug discrimination data and protocols across LSD, psilocybin, 5-MeO-DMT, and now psilocin.
Comparisons of psilocybin and 5-MeO-DMT benchmarking data have revealed potential differences in the mechanism of action related to the hallucinogenic experience of 5-MeO-DMT versus psilocybin. Furthermore, Mindset said the data suggest that the oral bioavailability of 5-MeO-DMT increases at higher doses in rodents.
READ: Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds
"In rodent drug discrimination studies, 5-HT2A antagonists completely block the ability of rats to perceive psilocybin, whereas the same antagonists do not completely block the effects of 5-MeO-DMT, suggesting that the perceptual experience of 5-MeO-DMT is due not only to 5-HT2A receptor agonism," said Joseph Araujo, chief scientific officer for Mindset, in a statement.
"Pharmacokinetics studies also show 5-MeO-DMT is not orally bioavailable at low doses, but at higher doses, 5-MeO-DMT is bioavailable and its half-life is prolonged, indicating that its metabolism is saturable. This exemplifies the importance of studying a range of doses of psychedelics for benchmarking purposes."
Mindset CEO James Lanthier added: "Mindset is developing a spectrum of differentiated, next-generation medical psychedelics with the goal of improving several factors compared to first-generation psychedelic drugs. Thanks to this detailed benchmarking data, we're better positioned to pre-clinically evaluate and assess drug candidates, which are essential towards reaching our treatment goals."
The COPE program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed.
Through this platform, Mindset said it and InterVivo intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo's facility.
The COPE platform is anticipated to represent an invaluable tool to guide the development of next-generation psychedelic compounds and improve the patentability and value of new potential drug assets.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham